News of Note—Teva accused of shortcutting plant sale; Sun plant gets only one observation

newspapers
(Pixabay)

> Teva has been sued by an Israeli businessman who claims his bid for the land use for two plants the drugmaker is closing in Jerusalem was overlooked. Story

> Sun Pharmaceutical has received on observation during a January FDA inspection of its plant in Halol. Form 483 (PDF)

> Strides says the FDA has approved a new dosage plant in Singapore. Filing (PDF)

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

> Shanghai-based WuXi STA has received EMA approval for a new drug product manufacturing facility in the Waigaoqiao Free Trade Zone of Shanghai. Release

> Lupin has received EU approval for a biologics plant in India. Story

> Cambrex says it has doubled the liquid filling capacity at its plant in Mirabel, Québec. Release

 

Suggested Articles

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.

Amidst a gung-ho shift to oncology, Daiichi is also fleshing out its gene therapy capacity with a $200 million licensing deal with Ultragenyx.